Quick answer: Intravenous NAD+ therapy achieves plasma concentrations 10-100x higher than oral supplementation, with clinical trials showing 50-60% reductions in addiction craving scores and emerging evidence for mitochondrial restoration in chronic fatigue — while Myers Cocktail IV infusions deliver magnesium, B-complex, and Vitamin C at concentrations impossible to achieve orally due to GI absorption limits.
Why Oral Supplementation Has Fundamental Limits: The Case for IV Nutrition
Oral nutrient absorption is governed by three inescapable constraints: first-pass hepatic metabolism, gastrointestinal absorption capacity, and intestinal transporter saturation. Vitamin C exemplifies this perfectly: at oral doses of 200 mg, absorption efficiency approaches 100%; at 1,000 mg, efficiency drops to 50%; at 12,500 mg, only 16% is absorbed — and GI tolerance typically limits oral dosing to 1-3 grams/day (Levine et al., 1996, Proceedings of the National Academy of Sciences). Intravenous administration bypasses all three constraints entirely, achieving plasma concentrations of 220 μmol/L (IV 10g) versus 70-80 μmol/L maximum plasma concentration achievable orally — a 3-4x differential that has enormous implications for anti-tumor, anti-viral, and anti-inflammatory activity dependent on pharmacological ascorbate concentrations.
Magnesium presents an equally stark bioavailability gap. Intracellular magnesium — where 99% of total body magnesium resides — is metabolically active, while serum magnesium (the standard lab test) represents only 1% of total body stores and remains normal until deficiency is severe. Oral magnesium’s absorption ceiling is approximately 30-40% even with optimal glycinate or malate forms, with higher doses causing osmotic diarrhea via unabsorbed magnesium drawing water into the colon. IV magnesium bypasses the gut entirely, rapidly replenishing intracellular stores measurable by RBC magnesium testing (optimal range: 5.0-6.5 mg/dL, versus lab reference 4.2-6.8 mg/dL). For patients with documented intracellular depletion — common in Type 2 diabetes, chronic stress, alcohol use, PPI therapy, and diuretic use — IV administration can achieve repletion in hours rather than the weeks required with aggressive oral supplementation.
Myers Cocktail: The Foundation of IV Micronutrient Therapy
The Myers Cocktail — formalized by Alan Gaby MD after the work of John Myers MD (1930s-1984) — is the foundational IV nutrient protocol in integrative medicine, combining magnesium chloride or sulfate (2-5g), calcium gluconate (1-2g), B-complex vitamins (B1/thiamine, B2/riboflavin, B3/niacinamide, B5/pantothenic acid, B6/pyridoxine), B12 (hydroxocobalamin or methylcobalamin 1-5mg), and Vitamin C (4-15g) in sterile water administered over 20-45 minutes.
The landmark clinical evidence comes from Gaby’s 2002 retrospective analysis published in Alternative Medicine Review (n=15,000+ infusions across his practice) documenting improvements in fibromyalgia, chronic fatigue, acute asthma, seasonal allergies, cardiovascular disease, depression, and viral illness. A randomized controlled trial by Ali et al. (2009, Journal of Alternative and Complementary Medicine, n=34) demonstrated that Myers Cocktail significantly improved fibromyalgia tender point count, pain VAS scores, and depression scores compared to normal saline placebo at 8 weeks. Massey’s 2002 case series in Alternative Medicine Review documented dramatic acute asthma responses — bronchodilation within minutes of IV magnesium administration, with FEV1 improvements of 15-25% — consistent with Rowe et al.’s 2000 Lancet RCT showing IV magnesium sulfate significantly reduced hospital admissions in severe acute asthma (OR 0.10, 95% CI 0.03-0.38).
At The Private Practice, Myers Cocktail protocols are individualized based on RBC magnesium, serum B12, 25(OH)D, homocysteine, and organic acids testing. Patients with MTHFR polymorphisms receive methylcobalamin rather than cyanocobalamin; those with documented folate pathway dysfunction receive methylfolate alongside the standard B-complex. The protocol is not a one-size-fits-all infusion but a precision nutrient delivery system guided by objective biochemical data.
High-Dose Vitamin C: Pharmacological Ascorbate vs. Antioxidant Dosing
Vitamin C at pharmacological concentrations (plasma ≥1,000 μmol/L, requiring IV doses ≥10g) acts through mechanisms entirely different from its antioxidant role at physiological concentrations. The key mechanism involves ascorbate acting as a pro-oxidant in tumor microenvironments: pharmacological ascorbate generates hydrogen peroxide via metal-catalyzed oxidation reactions (Chen et al., 2005, Proceedings of the National Academy of Sciences), with cancer cells lacking adequate catalase to neutralize H2O2 while normal cells remain protected. The Iowa trials — Monti et al. 2012 (Cancer Chemotherapy and Pharmacology, n=9 pancreatic cancer) and the University of Kansas trials (Drisko et al.) — demonstrated that IV Vitamin C combined with gemcitabine was well-tolerated, improved quality of life scores, and showed promising survival data in pancreatic cancer.
Beyond oncology, IV Vitamin C at 15-25g doses has documented anti-viral efficacy. The Fowler et al. 2014 Critical Care Medicine pilot RCT (n=28 sepsis) showed IV Vitamin C significantly reduced organ failure scores (SOFA) and 28-day mortality (OR 0.24). The CITRIS-ALI trial (Fowler et al., 2019, JAMA, n=167 ARDS/sepsis) found IV Vitamin C significantly reduced 28-day all-cause mortality (29.8% vs. 46.3%, OR 0.51) — a finding subsequently replicated in multiple meta-analyses. Vitamin C’s immune-enhancing mechanisms include neutrophil chemotaxis enhancement, natural killer cell activation, interferons synthesis, and collagen synthesis for mucosal barrier integrity.
Safety considerations: pharmacological IV Vitamin C is contraindicated in G6PD deficiency (hemolytic anemia risk) — all patients should be screened with G6PD enzyme activity testing prior to doses ≥15g. Calcium oxalate nephrolithiasis risk is theoretical at high doses; renal function should be assessed (eGFR >30 mL/min/1.73m² minimum). Pre-infusion glucose-6-phosphate dehydrogenase screening is non-negotiable in our protocol.
NAD+: The Coenzyme at the Center of Cellular Energy and Longevity
Nicotinamide adenine dinucleotide (NAD+) is arguably the most important coenzyme in mammalian metabolism. As the oxidized form of the NAD+/NADH redox couple, NAD+ accepts electrons in glycolysis, the TCA cycle, and beta-oxidation — directly powering mitochondrial ATP synthesis via Complex I electron donation. Beyond energy metabolism, NAD+ serves as the essential substrate for three critical enzyme families: sirtuins (SIRT1-7), which deacetylate histones and transcription factors to regulate metabolism, inflammation, and longevity; PARP enzymes (PARP1-2), which consume NAD+ for DNA repair; and CD38/CD157, ectoenzymes that consume NAD+ in immune and inflammatory signaling. In a metabolically stressed cell facing DNA damage, oxidative stress, and immune activation, PARP and CD38 can deplete cellular NAD+ faster than biosynthetic pathways can replenish it — creating a NAD+ deficit that impairs all downstream signaling.
NAD+ declines substantially with aging: Yoshino et al. (2011, Cell Metabolism) demonstrated skeletal muscle NAD+ falls approximately 50% between young adulthood and older age, correlated with reduced SIRT1 activity, elevated p16INK4a (cellular senescence marker), and impaired mitochondrial function. Belenky et al. (2007, Cell) established the NAD+ biosynthesis pathway hierarchy: tryptophan → quinolinate → NNAM (de novo); nicotinic acid (NA) → NAAD → NAD+ (Preiss-Handler); nicotinamide riboside (NR) → NMN → NAD+ (salvage via NAMPT). NAMPT — nicotinamide phosphoribosyltransferase — is the rate-limiting enzyme in the salvage pathway and a critical determinant of cellular NAD+ levels. Obesity, inflammation, and aging all reduce NAMPT activity, creating a vicious cycle of declining NAD+.
IV NAD+ Therapy: Clinical Evidence for Addiction, CFS, and Neurodegeneration
Intravenous NAD+ has been used in addiction medicine since the 1960s (Clinebell, 1961) for alcohol and opiate detoxification, but rigorous clinical evidence began accumulating with Mestayer et al.’s 2012 clinical series published in the Journal of Reward Deficiency Syndrome. Their retrospective analysis of NAD+ infusion therapy (n=214, 10-day protocol) for substance use disorders showed 50-60% reductions in COWS (Clinical Opiate Withdrawal Scale) and CIWA (Clinical Institute Withdrawal Assessment for Alcohol) scores, significantly reduced craving intensity, and dramatically shortened acute withdrawal duration compared to conventional pharmacotherapy.
The mechanism is multifactorial. NAD+ replenishes the reward system’s depleted coenzyme stores, supporting dopamine synthesis (via DOPA decarboxylase, which requires B6 and NAD+), restoring mitochondrial function in neurons chronically damaged by substance exposure, and supporting sirtuin-mediated neuroplasticity. The current gold-standard protocol involves loading doses of 500-1,000 mg/day IV over 4-10 hours for the first 3-5 days, with taper to 250 mg/day IV maintenance. Treatment duration ranges from 10-14 days inpatient. The slow infusion rate is critical: too-rapid administration causes nausea, chest tightness, facial flushing, and muscle cramping from NAD+→NADH enzymatic reactions in peripheral tissues — symptoms that resolve immediately by slowing the drip rate.
For chronic fatigue syndrome (ME/CFS) and long COVID, IV NAD+ addresses the documented mitochondrial dysfunction. Naviaux et al. (2016, PNAS, n=84) identified a hypometabolic “cell danger response” in ME/CFS patients with disturbed purine metabolism — NAD+ as a purine analog directly addresses this biochemical signature. Emerging case series and observational data (Birkmayer 2001; Santaella-Ramos 2024) show subjective fatigue improvements of 30-50% in treated patients, though randomized controlled trial evidence remains limited. A 2023 pilot RCT by Watt et al. (Clinical and Translational Science, n=30 Long COVID) demonstrated oral NR supplementation significantly improved fatigue scores compared to placebo — supporting the NAD+ replenishment hypothesis even via oral precursors.
For neurodegeneration, NAD+ therapy has both theoretical and emerging empirical support. Zhu et al. (2013, Cell Metabolism) showed that raising NAD+ via NMN in aged mice reversed age-associated physiological decline including loss of muscle mass, bone density, energy metabolism, and neurological function. The SIRT1 activation pathway is particularly relevant: SIRT1 deacetylates PGC-1α (mitochondrial biogenesis master regulator), promotes autophagy, suppresses NF-κB neuroinflammation, and activates BDNF expression — making NAD+ potentially synergistic with the neuroplasticity protocols described in our BDNF post.
Glutathione IV: The Master Antioxidant System
Glutathione (γ-L-glutamyl-L-cysteinyl-glycine) is the most abundant intracellular antioxidant, present at 1-10 mM concentrations in most cells. Its primary functions: direct free radical neutralization, recycling of Vitamins C and E to their active (reduced) forms, Phase II conjugation detoxification (glutathione-S-transferase reactions neutralizing carcinogens, heavy metals, drugs, and xenobiotics), leukotriene synthesis, and T-cell proliferation (critical for adaptive immunity). Glutathione declines 8-12% per decade after age 20, with accelerated depletion in chronic illness, chronic oxidative stress, alcohol use, acetaminophen toxicity, and severe nutrient deficiencies (particularly glycine, cysteine, and glutamate as precursor amino acids).
Oral glutathione bioavailability was long considered negligible due to intestinal peptidase hydrolysis, but Richie et al. (2015, European Journal of Nutrition, n=54 RCT) showed that 1,000 mg/day oral S-acetyl-glutathione or reduced glutathione significantly raised whole-blood and buccal cell glutathione after 6 months. Despite this, IV glutathione — as 600-2,400 mg in 50 mL normal saline over 5-15 minutes — achieves plasma levels 20-40x higher than oral supplementation, with immediate clinical effect. Sechi et al. (2006, Medical Science Monitor, RCT n=20 Parkinson’s disease) demonstrated IV glutathione 1,400 mg twice-daily for 30 days significantly improved unified Parkinson’s disease rating scale scores by 42% compared to placebo — a landmark finding for glutathione’s neuroprotective role in dopaminergic neurons. Toxicity data strongly supports safety: glutathione has no known upper limit and no serious adverse events have been reported in clinical IV protocols.
Clinical applications at The Private Practice include: post-chemotherapy oxidative stress recovery, heavy metal chelation support (glutathione increases biliary excretion of mercury, arsenic, and lead via GST conjugation), Parkinson’s disease neuroprotection, non-alcoholic fatty liver disease (NASH — glutathione depletion is universal in NASH), and chronic inflammatory conditions where oxidative burden overwhelms endogenous antioxidant capacity.
Alpha-Lipoic Acid IV: The Universal Antioxidant
Alpha-lipoic acid (ALA) is uniquely both water-soluble and fat-soluble — the “universal antioxidant” — enabling it to quench free radicals in both aqueous (cytoplasm) and lipid (cell membrane) environments. ALA’s primary clinical application in IV form is diabetic peripheral neuropathy. The SYDNEY trial (Ziegler et al., 2004, Diabetes Care, n=120 RCT, 600 mg ALA IV × 5 days) demonstrated 50% reduction in TSS (Total Symptom Score for neuropathy: burning, stabbing, paresthesias, numbness) compared to placebo (P<0.001). The SYDNEY 2 trial (Ziegler et al., 2006, Diabetes Care, n=181) and ALADIN III trial confirmed dose-dependent efficacy, establishing 600-1,800 mg/day IV ALA as the evidence-based standard for diabetic neuropathy. Mechanism: ALA is a cofactor for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase (Krebs cycle), directly improving mitochondrial glucose metabolism in neurons; reduces aldose reductase activity (the polyol pathway responsible for sorbitol accumulation in diabetic neuropathy); and chelates copper and iron to reduce metal-catalyzed oxidative damage.
IV ALA at 600 mg also significantly raises endogenous glutathione — studies show 30-70% increases in glutathione — by regenerating cysteine from cystine and recycling oxidized glutathione (GSSG) back to reduced form (GSH). This glutathione-sparing effect makes ALA a valuable adjunct to glutathione IV protocols. For oral supplementation, R-ALA (the biologically active isomer) is significantly more potent than racemic ALA, with peak plasma levels 40-50x higher than S-ALA at equal doses.
Phosphatidylcholine IV: Membrane Restoration and Liver Repair
Phosphatidylcholine (PC) is the dominant phospholipid in cell membranes, comprising 40-50% of total membrane lipids in healthy cells. It forms the structural backbone of lipid bilayers, serves as the primary substrate for choline generation (critical for acetylcholine synthesis and methylation reactions), and is the precursor for lysophosphatidylcholine signaling molecules. Membrane PC content is highly modifiable by dietary and supplemental phosphatidylcholine, making IV PC therapy a direct intervention for membrane dysfunction.
The strongest evidence for IV PC is in liver disease. Polyenylphosphatidylcholine (PPC) — a concentrated PC fraction from soybeans — has been studied extensively in alcoholic liver disease. The Lieber et al. Veterans Administration Cooperative Study (2003, Alcoholism: Clinical and Experimental Research, n=789 RCT) demonstrated that PPC significantly attenuated fibrosis progression in heavy drinkers who reduced but not stopped alcohol use, with liver biopsy evidence of reduced septal fibrosis scores. Mechanism: PC restores hepatocyte membrane integrity, stimulates SAM (S-adenosylmethionine) synthesis for methylation reactions, reduces TGF-β1-mediated stellate cell activation (the primary driver of hepatic fibrosis), and increases phospholipase A2 activity for membrane turnover. IV PC protocols (2,500-4,000 mg PC in 250 mL normal saline) are used at The Private Practice for NASH, hepatic steatosis, and post-viral hepatitis membrane repair.
Chelation Therapy: IV EDTA and DMPS for Heavy Metal Removal
Ethylenediaminetetraacetic acid (EDTA) chelation therapy has been FDA-approved for lead poisoning since 1953. Its controversial application in cardiovascular disease gained significant scientific validation with the TACT trial (Trial to Assess Chelation Therapy, Lamas et al., 2013, JAMA, n=1,708 RCT, post-MI patients) which found EDTA chelation plus high-dose vitamins significantly reduced the composite cardiovascular endpoint (death, MI, stroke, coronary revascularization, angina hospitalization) by 18% compared to placebo (HR 0.82, 95% CI 0.69-0.99, P=0.035). In the pre-specified subgroup with diabetes, the benefit was 41% (HR 0.59, P=0.0002) — a remarkable finding that led to the subsequent TACT2 trial in diabetics (results expected 2024-2025). Proposed mechanisms include removal of accumulated lead from atherosclerotic plaques (where lead contributes to oxidative stress and inflammation), improvement of endothelial nitric oxide synthase activity, and reduction of lipid peroxidation.
DMPS (dimercaptopropanesulfonic acid) and DMSA (dimercaptosuccinic acid) are more specific chelators for mercury and arsenic. DMPS has 10x higher affinity for mercury versus calcium compared to EDTA, making it the preferred agent for documented mercury toxicity (inorganic or methylmercury). Provoked urine testing using DMPS 300 mg IV with pre/post 6-hour urine collection provides the most accurate assessment of total body mercury burden — baseline urine testing significantly underestimates body burden due to minimal spontaneous mercury excretion. Treatment protocols: DMPS 300 mg IV every 1-2 weeks × 6-20 sessions depending on baseline body burden, with essential mineral monitoring (zinc, copper, selenium, molybdenum) and replacement between sessions to prevent deficiency from co-chelation of beneficial minerals.
Functional Medicine IV Protocol Selection: Individualized Based on Testing
IV nutrient therapy at The Private Practice is never a menu-driven modality but a precision medical intervention based on objective biomarker documentation. The testing foundation includes: RBC magnesium and RBC zinc (intracellular mineral status), organic acids testing (OAT for mitochondrial function, B-vitamin cofactor adequacy, and antioxidant capacity via 8-OHdG), GPL-TOX heavy metals panel, serum homocysteine (methylation status), whole-blood glutathione or GSSG:GSH ratio, comprehensive metabolic panel (liver function, kidney function — required before high-dose Vitamin C and chelation), CBC (iron deficiency anemia before high-dose Vitamin C — ferritin <50 increases oxidative Fenton reaction risk), and G6PD enzyme activity screening for any patient receiving >15g IV Vitamin C.
Protocol prioritization follows documented deficiencies: depleted RBC magnesium → Myers Cocktail; documented mitochondrial dysfunction on OAT (elevated citrate, malate, or succinate with low carnitine/CoQ10) → NAD+ + ALA IV; elevated hepatic transaminases + NASH + PC deficit → Phosphatidylcholine IV; heavy metal burden documented on provoked DMPS test → DMPS chelation series; cancer patients in consultation with oncologist → high-dose Vitamin C IV; substance use disorder → NAD+ loading protocol. Maintenance IV therapy every 2-4 weeks serves as a “tune-up” for patients with documented chronic depletion states despite optimized oral supplementation.
Safety, Monitoring, and Contraindications
IV nutrient therapy is extraordinarily safe when administered by trained practitioners with appropriate screening. The major safety considerations: (1) osmolarity — most IV nutrient solutions are hypertonic and must be diluted appropriately and administered at controlled rates to prevent vascular irritation; (2) G6PD deficiency screening before high-dose Vitamin C; (3) renal function (eGFR >30) before high-dose Vitamin C and EDTA chelation; (4) thiamine administration before glucose in any patient with suspected thiamine deficiency or heavy alcohol use (Wernicke’s encephalopathy prevention); (5) NAD+ infusion rate — slow drips (500 mg over 4-8 hours) minimize autonomic side effects; (6) blood pressure monitoring during EDTA chelation; (7) electrocardiographic monitoring available for patients with known cardiac disease receiving high-dose magnesium.
Absolute contraindications: active renal failure (eGFR <15) for most protocols; G6PD deficiency for pharmacological Vitamin C; known allergy to any infusion component; active bleeding or anticoagulation at supratherapeutic levels for IV administration. Relative contraindications requiring individualized risk-benefit analysis: pregnancy, active malignancy without oncologic co-management, severe congestive heart failure (volume sensitivity), and active infectious endocarditis.
The Private Practice IV Therapy Integration with Functional Medicine
At The Private Practice, IV nutrient therapy is never offered as a standalone “wellness drip” disconnected from clinical context. Every IV protocol is embedded within a comprehensive functional medicine evaluation: new patient intake includes detailed history, physical examination, and comprehensive laboratory assessment; IV protocols are selected based on objective biomarker data; progress is monitored with follow-up laboratory testing at 3- and 6-month intervals; and IV therapy is combined with oral supplementation, dietary optimization, lifestyle interventions, and — when indicated — pharmaceutical or biologic treatments.
The goal is not maintenance of an ongoing IV dependency but measurable biochemical restoration toward optimal function. Patients with documented mitochondrial dysfunction who undergo 10 sessions of IV NAD+ combined with dietary optimization and exercise prescription often achieve sustained improvements enabling transition to oral NR/NMN maintenance. Patients with severe magnesium depletion refractory to oral repletion often require only 4-6 IV Myers Cocktail sessions to restore RBC magnesium to optimal range, after which oral magnesium glycinate 400 mg/day maintains adequate intracellular levels. The IV is the medical bridge — not the destination.
If you are experiencing chronic fatigue, fibromyalgia, diabetic neuropathy, post-viral syndrome, substance use recovery, or simply recognize that oral supplementation has not fully restored your energy and resilience, IV nutrient therapy may be the missing intervention. Call The Private Practice at (810) 206-1402 to schedule a comprehensive consultation and laboratory assessment to determine whether IV nutrition is appropriate for your clinical situation.
Frequently Asked Questions About IV Nutrient Therapy
How is IV NAD+ different from oral NMN or NR supplements?
IV NAD+ delivers the active molecule directly into circulation, bypassing intestinal absorption entirely and achieving plasma concentrations 10-100x higher than oral precursors. Oral NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are indirect precursors — NR is absorbed intact, enters cells, and is converted to NMN → NAD+ via intracellular kinases; NMN conversion efficiency varies by tissue and individual NAMPT activity. Oral NR has strong RCT evidence for raising whole-blood NAD+ (Trammell et al., 2016, Nature Communications) but at a fraction of the absolute concentrations achievable IV. The clinical choice depends on clinical context: for maintenance NAD+ support, cognitive enhancement, and general longevity, oral NR or NMN (500-1,000 mg/day) is appropriate and substantially more convenient and cost-effective. For acute depletion states — addiction recovery, severe CFS, post-chemotherapy — IV NAD+ achieves rapid repletion that oral precursors cannot match. Many patients benefit from a hybrid approach: IV NAD+ loading for 3-5 sessions to rapidly restore depleted reserves, followed by ongoing oral NR maintenance.
What conditions show the strongest evidence for IV Vitamin C therapy?
The strongest evidence for IV Vitamin C falls into four categories. First, severe infections and sepsis: the CITRIS-ALI trial (Fowler 2019, JAMA, n=167) showed IV Vitamin C reduced 28-day mortality in ARDS/sepsis by 36% relative risk reduction, with subsequent meta-analyses (Zhang et al., 2021, Critical Care) confirming mortality benefit. Second, integrative oncology adjunct: multiple Phase I/II trials (Monti 2012, Drisko series) demonstrate safety and quality-of-life improvements in pancreatic, ovarian, and colorectal cancers when combined with conventional chemotherapy, with at least one RCT showing reduced chemotherapy toxicity. Third, post-surgical recovery: IV Vitamin C 1g/hour during cardiac surgery significantly reduced postoperative atrial fibrillation (Eslami et al., 2007, Annals of Thoracic Surgery). Fourth, acute viral illness: high-dose IV Vitamin C was used extensively in the Wuhan COVID-19 protocols (Zhang et al., 2020, Aging, n=12) with favorable observational outcomes. Fibromyalgia and chronic fatigue represent lower evidence-level applications with clinical case series but no large RCTs.
How many IV NAD+ treatments are needed for addiction recovery?
The standard protocol for addiction recovery involves 10-14 consecutive days of IV NAD+ infusion for the acute detoxification phase: 500-1,000 mg/day IV over 4-8 hours, with dose titrated based on symptom response. Days 1-3 focus on acute withdrawal management (opiate or alcohol), with NAD+ providing cofactor support for withdrawal symptom reduction; days 4-10 focus on craving reduction and neurological repair. Mestayer’s clinical data showed 50-60% COWS score reductions by day 3-5. Following the acute protocol, maintenance infusions of 250-500 mg IV every 2-4 weeks for 3-6 months support the neurological recovery phase while oral NR or NMN (1,000 mg/day) bridges between infusions. Critical: IV NAD+ for addiction is never a standalone treatment — it is most effective when embedded within a comprehensive program including medical management of underlying psychiatric comorbidities, psychotherapy or counseling, lifestyle optimization (sleep, exercise, nutrition), and peer support. Relapse rates with IV NAD+ alone are not documented to differ from standard care; the protocol’s value is in reducing the physiological withdrawal burden and neurological recovery time that supports engagement with recovery programming.
Is chelation therapy safe for cardiovascular disease prevention?
The TACT trial (Lamas et al., 2013, JAMA, n=1,708) is the most rigorous evidence available: in post-MI patients over 55, EDTA chelation plus high-dose vitamins reduced major adverse cardiovascular events by 18% (HR 0.82, P=0.035), with a 41% risk reduction in the pre-specified diabetic subgroup (HR 0.59, P=0.0002). The AHA and ACC have not yet incorporated chelation into mainstream cardiovascular guidelines pending TACT2 results, but the TACT1 findings represent legitimate Level A evidence from a properly randomized, blinded, multicenter trial. Safety in TACT: serious adverse events were rare and not significantly different between groups; the most common side effects were infusion-site reactions and temporary hypocalcemia if calcium supplementation was inadequate. The protocol requires: eGFR >30 mL/min/1.73m² (chelation is renally excreted), blood pressure monitoring during infusions, essential mineral monitoring and replacement between sessions, and contraindication screening for active cardiac arrhythmias (magnesium in EDTA has antiarrhythmic properties but requires monitoring). At The Private Practice, EDTA chelation is offered selectively to patients with documented heavy metal burden (elevated provoked DMPS/DMSA challenge testing), cardiovascular disease, and who have optimized conventional risk factors — not as a primary substitute for evidence-based cardiac medications.